bluuebunny/crossref_metadata_2025_split huggingface dataset:
Chronic physical health conditions and associated factors among people with serious orthopaedic injuries: A systematic review
Authors: Gelaw Asmare Yitayeh , Gabbe Belinda J , Braaf Sandra C , McPhail Steven , Ekegren Christina L 
Published: November 2020

Introduction A clear understanding of the development of chronic physical health conditions following orthopaedic injury is essential to fully recognise the magnitude and burden of injury, improve treatment and predict certain outcomes. This review aimed at systematically identifying and evaluating current evidence of the incidence and prevalence of chronic physical health conditions and factors associated with chronic physical health conditions following serious orthopaedic injury. Materials and method Systematic literature search was performed using Ovid MEDLINE, Scopus, and Embase via Ovid, Cochrane Library and Ovid Emcare up to 30 December 2018. Observational studies relating to the incidence or prevalence of chronic physical health conditions and associated factors in people with serious orthopaedic injuries were included. Data extraction and methodological quality assessment were carried out independently by 2 reviewers. Result Of the 4835 references identified in the initial search, only five studies with sample sizes ranging from 83 to 3846 met the criteria for inclusion. The most prevalent conditions reported in people with serious orthopaedic injury included coronary artery disease, arrhythmias, myocardial infarction, hypertension, diabetes mellitus and chronic heart failure. Bronchial, rectal, prostate and breast cancers were also causes of late death in orthopaedic injury survivors. Most of the studies included in this review were unable to determine whether these conditions were related to injuries. Conclusions Chronic physical health conditions are prevalent among people with serious orthopaedic injury. Little is known about factors associated with chronic physical health conditions following serious orthopaedic injury or whether physical health conditions are associated with injury. Further work needs to be done to identify causal pathways and the longer-term effects of orthopaedic injury on the risk of developing chronic physical health conditions.
Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node
Authors: Zhi Yunfei , Lin Zhousheng , Ma Jinyuan , Mou Weiming , Chen Xinhua 
Published: November 2020

Background: Although the landmark INT-0116 trial and National Comprehensive Cancer Network (NCCN) guidelines recommended pT3-4Nx gastric cancer (GC) patients to receive chemoradiotherapy, the role of radiotherapy has not been distinguished from chemoradiotherapy. Methods: GC with behavior of metastasis-indolent in lymph node (MILN) being confirmed with more than 15 examined LNs after gastrectomy were identified using the Surveillance, Epidemiology and End Result (SEER) database. The cancer-specific survival (CSS) of subgroups for radiotherapy, chemotherapy, chemoradiotherapy and non-adjuvant-treatment were compared. Propensity score matching (PSM) was performed between radiotherapy and non-radiotherapy subgroups to further distinguish the role of radiotherapy from chemoradiotherapy. Cox regression was performed to identify whether radiotherapy or chemotherapy could independently improve prognosis. Results: We identified 690 MILN GC patients in SEER database. 5-year CSS was 71.9% in radiotherapy subgroup and 75.1% in non-radiotherapy subgroup(HR = 1.013, 95% CI = 0.714-1.438, p = 0.940), 75.6% in chemotherapy subgroup and 68.5% in non-chemotherapy subgroup(HR = 0.616, 95% CI = 0.430-0.884, p = 0.008), 52.5% in radiotherapy-alone subgroup and 71.9% in non-adjuvant treatment group (HR = 1.604, 95% CI = 0.575-4.471, p = 0.360), 72.9% in chemoradiotherapy subgroup and 79.5% in chemotherapy-alone subgroup (HR = 1.365, 95% CI = 0.859-2.172, p = 0.185), respectively. Further, PSM markedly improved balance of variables between radiotherapy subgroup and non-radiotherapy subgroup. After PSM, the role of the variables of radiotherapy and chemotherapy in contributing to improving CSS are consistent with that before PSM. Cox regression showed chemotherapy, tumor size, tumor invasiveness and Lauren classification were independent prognostic factors, but not including radiotherapy. Conclusions: Chemoradiotherapy confers superior prognosis to MILN GC patients compared with surgery alone might only be attributed to chemotherapy rather than radiotherapy.
Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis
Authors: He Ying , Wang Jing , Ma Chun-Xing , Kang Yan-Hua 
Published: November 2020

Background: Human epididymis protein 4 (HE4) is a novel cancer biomarker. This study evaluates the prognostic role of HE4 in determining the survival of endometrial cancer patients. Methods: Literature search was conducted in electronic databases (Embase, Ovid, PubMed, Scopus, and Web of Science). Studies were selected if they reported the relationship between HE4 and the survival of endometrial cancer patients. Random-effects meta-analyses were performed to achieve estimates of baseline serum HE4 levels, the 5-year survival with high and low serum HE4 levels/expression, and the hazard ratios (HRs) of the survival between patients with high and low serum HE4 levels. Results: 9 studies (1404 patients; age 63.1 years [95% confidence interval (CI): 61.2, 64.9]; follow-up 35.9 months [95% CI: 32.2, 39.6]) were included. In these patients, serum HE4 levels were 83.36 picomole/liter (pM) [95% CI: 70.15, 96.56] overall but these were higher in patients with recurrence (108.13 pM [95% CI: 63.09, 153.18] and lower in patients with no recurrence (67.88 pM [95% CI: 65.09, 70.67]). The 5-year overall survival rate was higher in patients with low HE4 levels/expression (86% [95% CI: 79, 92] but lower in patients with high HE4 levels/expression (63% [95% CI: 58, 68]. A pooled HR of survival between patients with high and low serum HE4 levels of 2.25 [95% CI: 1.56, 2.94] indicated shorter survival in patients with high serum HE4 levels. Conclusion: High HE4 concentrations in patients with endometrial cancer are found to be associated with shorter survival.
Management of large bore access complications in the era of trans-catheter aortic valve replacement
Authors: Parker Michael H , Mukherjee Dipankar , Ryan Liam 
Published: November 2020

Objectives Trans-catheter aortic valve replacement is a commonplace procedure for patients with aortic valvular stenosis who are at a high risk for surgery, evidenced by the 34,892 trans-catheter aortic valve replacements performed in 2016. Trans-catheter aortic valve replacement’s rate of major vascular complications with second-generation closure devices is 4.5% according to a meta-analysis of 10,822 patients. To manage those complications, percutaneous approaches to arterial repairs show shorter length of stay, higher rate of direct to home discharge and equivalent outcomes at long-term follow-up. This study’s goal is to show that one center’s vascular access strategy can decrease open repairs and improve patient outcomes. Methods Our team began accessing the mid-common femoral artery at least 1–2 cm proximal to the takeoff of the profunda femoris. This allowed an endovascular stent to be deployed if necessary via contralateral femoral access. We performed a completion angiogram following every trans-catheter aortic valve replacement to ensure no arterial complications. We conducted a retrospective review of a prospectively maintained database for all trans-catheter aortic valve replacement cases at a tertiary care center from 1 January 2016 to 30 June 2018. Results A total of 699 trans-catheter aortic valve replacement procedures were performed with 25/31 (80.6%) cases met inclusion criteria. An increase was noted in the number of stent procedures versus cutdown procedures over time ( P < 0.001). A decrease was noted in the number of vascular surgery team activations following trans-catheter aortic valve replacement ( P = 0.004). A non-significant trend was noted toward a shorter median length of stay for the stent group ( P = 0.149). There was no increase in 30-day mortality rate (0.0% for both groups) or 30-day readmissions (4/15 (26.7%) for stents vs. 2/10 (20.0%) for open repairs; P > 0.999). Conclusions This strategy is safe and feasible to implement and reduces the number of open repairs following trans-catheter aortic valve replacement, activation of surgical resources, and possibly the length of stay.
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Authors: Zhang Zhibo , Zhang Fan , Yuan Fang , Li Ye , Ma Junxun , Ou Qiuxiang , Liu Zhefeng , Yang Bo , Wang Lijie , Tao Haitao , Zhang Sujie , Li Xiaoyan , Zhi Xiaoyu , Ge Xiangwei , Bao Hua , Wu Xue , Hu Yi , Wang Jinliang 
Published: November 2020

Background: Targeting immune checkpoints represents an immense breakthrough in cancer therapeutics. The prognostic value of hemoglobin (Hb) has been investigated in many malignancies including non-small cell lung cancer (NSCLC). However, the prognostic impact of pretreatment Hb count for immune checkpoint inhibitors (ICIs) in advanced NSCLC patients remains unclear. Methods: A total of 310 late-stage NSCLC patients who received ICI therapies between January 2015 and March 2019 were prospectively enrolled. We used a propensity score-matched cohort analysis for this study. Patients’ clinicopathological characteristics and pretreatment Hb concentration were assessed against the progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method and Cox proportional hazards regression. Results: A propensity score (PS)-matched cohort analysis was applied to adjust for potential bias and to create two comparable groups according to patients’ clinicopathological characteristics. The patients with normal baseline Hb levels (⩾110 g/L) had significantly longer PFS [median: 10.0 versus 4.0 months, hazard ratio (HR): 0.63, 95% confidence interval (CI): 0.46−0.86; p = 0.001] and OS [median: 17.6 versus 10.5 months, HR (95% CI): 0.56 (0.40−0.79); p < 0.001] than those with decreased Hb count (<110 g/L) in a PS-matched cohort ( n = 255). For patients with normal pretreatment Hb levels, ICI combination therapy was significantly associated with better PFS [median: 11.1 versus 8.0 months, HR (95% CI): 0.74 (0.50−1.06); p = 0.09] and OS [median: 26.0 versus 12.9 months, HR (95% CI): 0.56 (0.37−0.86); p = 0.008] than monotherapy, but there was no such trend for patients with decreased baseline Hb levels. Conclusion: Our findings showed that normal pretreatment Hb count served as a favorable prognostic marker in advanced NSCLC patients treated with ICIs, representing an economical biomarker with readily measuring performance among all reported ones.
OASIS 1: Retrospective analysis of four different microprocessor knee types
Authors: Campbell James H , Stevens Phillip M , Wurdeman Shane R 
Published: November 2020

Introduction Microprocessor knee analyses to date have been primarily limited to microprocessor knees as a category rather than comparisons across different models. The purpose of the current analysis was to compare outcomes from four common knee models. Methods A retrospective analysis of clinical outcomes was performed. Outcomes for functional mobility, quality of life, satisfaction with amputee status, and injurious falls were compared. Specific knee types represented were C-Leg (Ottobock), Orion (Blatchford), Plié (Freedom Innovations), and Rheo (Össur). Results Outcomes from 602 individuals were included. No significant differences were noted for functional mobility (H = 2.91, p = 0.406) or satisfaction (H = 4.43, p = 0.219). For quality of life, differences existed for C-Leg versus Plié (p = 0.010). For injurious falls, C-Leg (χ2(1,137) = 10.99, p < 0.001) and Orion (χ2(1,119) = 4.34, p = 0.037) resulted in significantly reduced injurious falls compared to non-microprocessor knee users. C-Leg (H = 19.63, p < 0.001) and Plié (H = 14.04, p = 0.003) users saw declines with advanced aging. Conclusions Our data indicate relative parity among the 4 microprocessor knees with regard to functional mobility and satisfaction. In contrast to mobility, neither satisfaction nor quality of life values reflected declines with aging. Finally, when compared to non-microprocessor knees, significant differences were observed across the microprocessor knee types in relation to the reduction of injurious falls. Keywords: MPK, mobility, quality of life, falls, amputee, outcomes
Repair of Incidental Durotomy Using Sutureless Nonpenetrating Clips via Biportal Endoscopic Surgery
Authors: Heo Dong Hwa , Ha Ji Soo , Lee Dong Chan , Kim Hyeun Sung , Chung Hoon Jae 
Published: November 2020

Study Design: Technical report. Objectives: Dural tear is one of the most common complications of endoscopic spine surgery. Although endoscopic dural repair of the durotomy area may be difficult, we successfully repaired the dural tear area using nonpenetrating clips during biportal endoscopic surgery. We introduce the surgical technique of dural repair using nonpenetrating titanium clips in biportal endoscopic spine surgery and report its clinical outcome. Methods: We retrospectively reviewed and analyzed 5 patients who were treated via primary dural repair using nonpenetrating titanium clips during biportal endoscopic lumbar surgery. The 2 methods of dural clipping and repair include 2 or 3 portals. We analyzed radiological parameters such as cerebrospinal fluid collection as well as clinical parameters, including postoperative clinical outcomes. Results: Five patients underwent biportal endoscopic dural repair using nonpenetrating clips. Incidental durotomy was successfully repaired using nonpenetrating titanium clips in all 5 patients. No cerebrospinal fluid collection was detected in the postoperative magnetic resonance images. Clinically, preoperative symptoms improved significantly after surgery ( P < .05). Conclusions: We repaired the dural tear area completely using nonpenetrating titanium vascular anastomosis clips in biportal endoscopic lumbar surgery. Dural repair via clipping method may be an effective alternative for incidental durotomy.
Progression signature underlies clonal evolution and dissemination of multiple myeloma
Authors: Shen Yu Jia , Mishima Yuji , Shi Jiantao , Sklavenitis-Pistofidis Romanos , Redd Robert A. , Moschetta Michele , Manier Salomon , Roccaro Aldo M. , Sacco Antonio , Tai Yu-Tzu , Mercier Francois , Kawano Yawara , Su Nang Kham , Berrios Brianna , Doench John G. , Root David E. , Michor Franziska , Scadden David T. , Ghobrial Irene M. 
Published: November 2020

Abstract
Clonal evolution drives tumor progression, dissemination, and relapse in multiple myeloma (MM), with most patients dying of relapsed disease. This multistage process requires tumor cells to enter the circulation, extravasate, and colonize distant bone marrow (BM) sites. Here, we developed a fluorescent or DNA-barcode clone-tracking system on MM PrEDiCT (progression through evolution and dissemination of clonal tumor cells) xenograft mouse model to study clonal behavior within the BM microenvironment. We showed that only the few clones that successfully adapt to the BM microenvironment can enter the circulation and colonize distant BM sites. RNA sequencing of primary and distant-site MM tumor cells revealed a progression signature sequentially activated along human MM progression and significantly associated with overall survival when evaluated against patient data sets. A total of 28 genes were then computationally predicted to be master regulators (MRs) of MM progression. HMGA1 and PA2G4 were validated in vivo using CRISPR-Cas9 in the PrEDiCT model and were shown to be significantly depleted in distant BM sites, indicating their role in MM progression and dissemination. Loss of HMGA1 and PA2G4 also compromised the proliferation, migration, and adhesion abilities of MM cells in vitro. Overall, our model successfully recapitulates key characteristics of human MM disease progression and identified potential new therapeutic targets for MM.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia
Authors: Gottschalk Højfeldt Sofie , Grell Kathrine , Abrahamsson Jonas , Lund Bendik , Vettenranta Kim , Jónsson Ólafur G. , Frandsen Thomas L. , Wolthers Benjamin O. , Marquart Hanne Vibeke , Vaitkeviciene Goda , Lepik Kristi , Heyman Mats , Schmiegelow Kjeld , Albertsen Birgitte Klug 
Published: November 2020

Abstract
Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal asparaginase exposure among 1401 children aged 1 to 17 years, diagnosed with ALL between July 2008 and February 2016, treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol (including extended asparaginase exposure [1000 IU/m2 intramuscularly weeks 5-33]). Patients were included with delayed entry at their last administered asparaginase treatment, or detection of SI, and followed until relapse, death, secondary malignancy, or end of follow-up (median, 5.71 years; interquartile range, 4.02-7.64). In a multiple Cox model comparing patients with (n = 358) and without (n = 1043) truncated asparaginase treatment due to clinical toxicity, the adjusted relapse-specific hazard ratio (HR; aHR) was 1.33 (95% confidence interval [CI], 0.86-2.06; P = .20). In a substudy including only patients with information on enzyme activity (n = 1115), the 7-year cumulative incidence of relapse for the 301 patients with truncation of asparaginase treatment or SI (157 hypersensitivity, 53 pancreatitis, 14 thrombosis, 31 other, 46 SI) was 11.1% (95% CI, 6.9-15.4) vs 6.7% (95% CI, 4.7-8.6) for the 814 remaining patients. The relapse-specific aHR was 1.69 (95% CI, 1.05-2.74, P=.03). The unadjusted bone marrow relapse-specific HR was 1.83 (95% CI, 1.07-3.14, P=.03) and 1.86 (95% CI, 0.90- 3.87, P=.095) for any central nervous system relapse. These results emphasize the importance of therapeutic drug monitoring and appropriate adjustment of asparaginase therapy when feasible. This trial was registered at www.clinicaltrials.gov as #NCT03987542.
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
Authors: Coppo Paul , Bubenheim Michael , Azoulay Elie , Galicier Lionel , Malot Sandrine , Bigé Naïke , Poullin Pascale , Provôt François , Martis Nihal , Presne Claire , Moranne Olivier , Benainous Ruben , Dossier Antoine , Seguin Amélie , Hié Miguel , Wynckel Alain , Delmas Yahsou , Augusto Jean-François , Perez Pierre , Rieu Virginie , Barbet Christelle , Lhote François , Ulrich Marc , Rumpler Anne Charvet , de Witte Sten , Krummel Thierry , Veyradier Agnès , Benhamou Ygal 
Published: November 2020

Abstract
The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective controlled trials. However, few data are available on postmarketing surveillance. We treated 90 iTTP patients with a compassionate frontline triplet regimen associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab. Outcomes were compared with 180 historical patients treated with the standard frontline treatment (TPE and corticosteroids, with rituximab as salvage therapy). The primary outcome was a composite of refractoriness and death within 30 days since diagnosis. Key secondary outcomes were exacerbations, time to platelet count recovery, the number of TPE, and the volume of plasma required to achieve durable remission. The percentage of patients in the triplet regimen with the composite primary outcome was 2.2% vs 12.2% in historical patients (P = .01). One elderly patient in the triplet regimen died of pulmonary embolism. Patients from this cohort experienced less exacerbations (3.4% vs 44%, P &lt; .01); they recovered durable platelet count 1.8 times faster than historical patients (95% confidence interval, 1.41-2.36; P &lt; .01), with fewer TPE sessions and lower plasma volumes (P &lt; .01 both). The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P &lt; .01). Caplacizumab-related adverse events occurred in 46 patients (51%), including 13 major or clinically relevant nonmajor hemorrhagic events. Associating caplacizumab to TPE and immunosuppression, by addressing the 3 processes of iTTP pathophysiology, prevents unfavorable outcomes and alleviates the burden of care.
PM2.5 exposure and DLEC1 promoter methylation in Taiwan Biobank participants
Authors: Chou Ying-Hsiang , Tantoh Disline Manli , Wu Ming-Chi , Tyan Yeu-Sheng , Chen Pei-Hsin , Nfor Oswald Ndi , Hsu Shu-Yi , Shen Chao-Yu , Huang Chien-Ning , Liaw Yung-Po 
Published: November 2020

AbstractBackgroundParticulate matter (PM) < 2.5 μm (PM2.5) or fine PM is a serious public health concern. It affects DNA methylation and heightens carcinogenesis. Deleted in lung and esophageal cancer 1 (DLEC1) is a tumor suppressor gene. However, aberrant methylation of the gene is associated with several cancers. We evaluated the association between PM2.5and DLEC1 promoter methylation in Taiwanese adults based on regular outdoor exercise.MethodsWe obtained DNA methylation and exercise data of 496 participants (aged between 30 and 70 years) from the Taiwan Biobank (TWB) database. We also extracted PM2.5data from the Air Quality Monitoring Database (AQMD) and estimated participants’ exposure using residential addresses.ResultsDLEC1 methylation and PM2.5were positively associated: beta coefficient (β) = 0.114 × 10−3;pvalue = 0.046. The test for interaction between exercise and PM2.5on DLEC1 methylation was significant (pvalue = 0.036). After stratification by exercise habits, PM2.5and DLEC1 methylation remained significantly associated only among those who exercised regularly (β= 0.237 × 10−3;pvalue = 0.007). PM2.5quartile-stratified analyses revealed an inverse association between regular exercise and DLEC1 methylation at PM2.5< 27.37 μg/m3(β= − 5.280 × 10−3;pvalue = 0.009). After combining exercise habits and PM2.5quartiles, one stratum (i.e., regular exercise and PM2.5< 27.37 μg/m3) was inversely associated with DLEC1 methylation (β= -5.160 × 10−3,pvalue = 0.007).ConclusionsWe found significant positive associations between PM2.5and DLEC1 promoter methylation. Regular exercise at PM2.5< 27.37 μg/m3seemingly regulated DLEC1 promoter methylation.